BeOne Medicines Ltd. — fact timeline

Qingqing Yi departed as Director at BeOne Medicines Ltd..

“Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.”

Corazon (Corsee) D. Sanders departed as Director at BeOne Medicines Ltd..

“Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.”

Ranjeev Krishana departed as Director at BeOne Medicines Ltd..

“Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.”

Michael Goller departed as Director at BeOne Medicines Ltd..

“Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.”

BeOne Medicines Ltd. shareholders approved Proposal to approve the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period at the 2026-06-11 meeting.

“Proposal to approve the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period: Votes For Votes Against Abstentions Broker Non-Votes 980,858,936 47,367,478 32,793,555 — Accordingly, the maximum aggregate compensation of the Board of Directors under Swiss law for the applicable period was approved.”

BeOne Medicines Ltd. shareholders approved Proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, for fiscal year ended December 31, 2025 at the 2026-06-11 meeting.

“Proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, for fiscal year ended December 31, 2025: Votes For Votes Against Abstentions Broker Non-Votes 975,327,100 52,877,460 32,815,949 — Accordingly, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in the Proxy Statement, was approved.”

BeOne Medicines Ltd. shareholders approved Proposal to authorize the Board of Directors to fix the auditors' compensation for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal to authorize the Board of Directors to fix the auditors' compensation for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions Broker Non-Votes 1,022,450,031 3,162,724 35,208,860 — Accordingly, the Board of Directors was authorized to fix the auditors' compensation for the fiscal year ending December 31, 2026.”

BeOne Medicines Ltd. shareholders approved Proposal to ratify the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 and to re-elect Ernst & Young AG as the Company's statutory auditor for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal to ratify the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors for the fiscal year ending December 31, 2026 and to re-elect Ernst & Young AG as the Company's statutory auditor for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions Broker Non-Votes 1,052,800,458 8,153,634 72,817 — Accordingly, the appointment of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company's independent auditors was ratified and Ernst & Young AG was re-elected as the Company's statutory auditor.”

BeOne Medicines Ltd. shareholders approved Proposal to elect Schweiger Advokatur/Notariat as the Independent Voting Representative for a term extending until completion of the 2027 annual general meeting at the 2026-06-11 meeting.

“Proposal to elect Schweiger Advokatur/Notariat as the Independent Voting Representative for a term extending until completion of the 2027 annual general meeting: Votes For Votes Against Abstentions Broker Non-Votes 1,028,087,301 150,289 32,789,319 — Accordingly, Schweiger Advokatur/Notariat was elected as the Independent Voting Representative.”

BeOne Medicines Ltd. shareholders approved Proposal to re-elect Dr. Margaret Dugan and to elect Ms. Elizabeth F. Mooney to serve as a member of the Compensation Committee of the Board of Directors for a term extending until the 2027 annual general meeting at the 2026-06-11 meeting.

“Proposal to re-elect Dr. Margaret Dugan and to elect Ms. Elizabeth F. Mooney to serve as a member of the Compensation Committee of the Board of Directors for a term extending until the 2027 annual general meeting: Nominee Votes For Votes Against Abstentions Broker Non-Votes Dr. Margaret Dugan 1,012,836,634 15,408,489 32,781,786 — Ms. Elizabeth F. Mooney 1,028,055,025 172,249 32,799,635 — Accordingly, each of the nominees listed above was elected to serve as a member of the Compensation Committee of the Board of Directors.”

BeOne Medicines Ltd. shareholders approved Proposal to re-elect Mr. John V. Oyler as Chairman of the Board of Directors for a term extending until completion of the 2027 annual general meeting at the 2026-06-11 meeting.

“Proposal to re-elect Mr. John V. Oyler as Chairman of the Board of Directors for a term extending until completion of the 2027 annual general meeting: Votes For Votes Against Abstentions Broker Non-Votes 939,342,084 88,905,363 32,779,462 — Accordingly, Mr. John V. Oyler was re-elected to serve as Chairman of the Board of Directors.”

BeOne Medicines Ltd. shareholders approved Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director for a at the 2026-06-11 meeting.

“Proposal to re-elect each of Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Anthony C. Hooper, Mr. John V. Oyler, Dr. Alessandro Riva, Ms. Shalini Sharp, and Dr. Xiaodong Wang, and to elect each of Dr. Felix J. Baker, Ms. Elizabeth F. Mooney and Dr. Charles L. Sawyers to serve as a director for a term extending until completion of the 2027 annual general meeting: Nominee Votes For Votes Against Abstentions Broker Non-Votes Dr. Olivier Brandicourt 1,022,508,944 5,736,979 32,780,986 — Dr. Margaret Dugan 1,011,658,169 16,567,756 32,794,584 — Mr. Anthony C. Hooper 997,703,483 29,570,339 33,746,687 — Mr. John V. Oyler 1,013,945,040 12,727,593 34,347,876 — Dr. Alessandro Riva 708,200,626 320,024,909 32,794,974 — Ms. Shalini Sharp 998,811,368 28,636,943 33,572,198 — Dr. Xiaodong Wang 1,022,595,038 5,650,686 32,774,785 — Dr. Felix J. Baker 856,267,633 171,971,786 32,781,090 — Ms. Elizabeth F. Mooney 1,028,073,956 152,008 32,794,545 — Dr. Charles L. Sawyers 1,028,075,907 146,090 32,804,912 —”

BeOne Medicines Ltd. shareholders approved Proposal to discharge the members of the Board of Directors and the Executive Management Team from liability for activities during the applicable period under Swiss law at the 2026-06-11 meeting.

“Proposal to discharge the members of the Board of Directors and the Executive Management Team from liability for activities during the applicable period under Swiss law: Votes For Votes Against Abstentions Broker Non-Votes 816,696,880 2,683,088 177,864,348 — Accordingly, the members of the Board of Directors and the Executive Management Team were discharged from liability for such activities during the applicable period.”

BeOne Medicines Ltd. shareholders approved Proposal to approve the appropriation of the accumulated loss for fiscal year 2025 at the 2026-06-11 meeting.

“Proposal to approve the appropriation of the accumulated loss for fiscal year 2025: Votes For Votes Against Abstentions Broker Non-Votes 1,028,050,311 180,369 32,789,829 — Accordingly, the appropriation of the accumulated loss for fiscal year 2025 was approved.”

BeOne Medicines Ltd. shareholders approved Proposal to approve the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 at the 2026-06-11 meeting.

“Proposal to approve the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025: Votes For Votes Against Abstentions Broker Non-Votes 1,026,904,777 175,000 33,940,732 — Accordingly, the audited Swiss statutory standalone financial statements and the audited Swiss statutory consolidated financial statements of the Company for fiscal year 2025 were approved.”

BeOne Medicines Ltd. reported the three months ended March 31, 2026 results: revenue Total revenue $1,513,438, net income GAAP net income $227,357, EPS GAAP diluted EPS per ADS $1.96.

“U.S. dollars and unaudited) Three Months Ended March 31, 2026 2025 % Change Net product revenues $ 1,487,329 $ 1,108,530 34 % Other revenue $ 26,109 $ 8,749 198 % Total revenue $ 1,513,438 $ 1,117,279 35 % GAAP income from operations $ 249,902 $ 11,102 2,151 % Adjusted income from operations* $ 414,394 $ 139,357 197 % GAAP net income $ 227,357 $ 1,270 17,802 %”

BeOne Medicines Ltd. terminated CMB Credit Facility with China Merchants Bank Co., Ltd. valued at Repaid in full all outstanding amounts, terminated all commitments and guarantees, no termination pe (effective 2025-12-16).

“On December 16, 2025, the Company utilized a portion of the proceeds from borrowings under the Facilities Agreement to repay in full all outstanding amounts owed under the Company’s Facility Agreement, dated as of December 9, 2024, by and between the Company and China Merchants Bank Co., Ltd. (the “CMB Credit Facility”), and terminated all commitments by the lender to extend further credit under the CMB Credit Facility and all guarantees and security interests granted by the Company to the lender under the CMB Credit Facility.”

BeOne Medicines Ltd. incurred debt of $885 million upfront payment, with option for up to $65 million additional with Royalty Pharma Investments 2023 ICAV maturing sixty days after the latest of: on a country-by-country basis, (i) the date on which the exploitation of any such Imdelltra Product no longer infringes an appli.

“(the “Company”), BeOne Medicines I GmbH (the “Seller”), a subsidiary of the Company, and Royalty Pharma Investments 2023 ICAV (“Royalty Pharma”) entered into a Royalty Purchase Agreement (the “Royalty Purchase Agreement”).”

BeOne Medicines Ltd.: Company continued from Cayman Islands to Switzerland; adopted Swiss Articles and Organizational Regulations, replacing the prior Seventh Amended and Restated Memorandum and Articles of Association (effective 2025-05-27).

“The Swiss Articles and Organizational Regulations became effective as of May 27, 2025 in connection with the Continuation.”

Shalini Sharp was appointed as Director at BeOne Medicines Ltd..

“appointed Shalini Sharp to the Board to fill the vacancy, effective September 27, 2024.”

Julia Wang resigned as Chief Financial Officer at BeOne Medicines Ltd..

“On July 17, 2024, Julia Wang, the Company’s current CFO, resigned as CFO effective July 19, 2024.”

Aaron Rosenberg was appointed as Chief Financial Officer at BeOne Medicines Ltd..

“On July 18, 2024, BeiGene, Ltd. (the “Company”) announced the appointment of Aaron Rosenberg as the Chief Financial Officer (“CFO”) and the principal financial officer of the Company, effective as of July 22, 2024 (the “Effective Date”).”

BeOne Medicines Ltd. reported the three months ended March 31, 2024 results: revenue $752 million.

“as Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Reports First Quarter 2024 Financial Results and Business Updates • Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period • BRUKINSA revenue of $489 million, driven by growth in the U.S. and”

Julia Wang changed role as Chief Financial Officer at BeOne Medicines Ltd..

“Mr. Ball assumes the role of principal accounting officer from Julia Wang, the Company’s Chief Financial Officer, who previously served as the Company’s principal financial officer and principal accounting officer.”

BeOne Medicines Ltd. reported three months and year ended December 31, 2023 results: revenue $634.4 million and $2.5 billion.

“EX-99.1 (EX-99.1) --- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates • Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods • Strengthened leadership in hematology with global BRUKINSA®”

Olivier Brandicourt was appointed as Director at BeOne Medicines Ltd..

“On January 23, 2024, the Board appointed Olivier Brandicourt, M.D. to the Board to fill the vacancy.”

Thomas Malley resigned as Director at BeOne Medicines Ltd..

“On January 22, 2024, Thomas Malley resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).”

BeOne Medicines Ltd. reported the three months ended September 30, 2023 results: revenue total revenue of $781 million, net income Net Income ... $215.4 million.

“Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates • Generated total revenue of $781 million and global product sales of $595 million, a 102% and 70% increase from the prior-year period, respectively, while steadily improving operating leverage • Global sales of BRUKINSA”

BeOne Medicines Ltd. terminated Mutual Termination and Release Agreement with Novartis Pharma AG (effective 2023-09-17).

“On September 17, 2023, BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Agreement”) to mutually terminate the License Agreement, effective immediately.”

BeOne Medicines Ltd. reported the three months ended June 30, 2023 results: revenue $553.7 million, net income $381.1 million, EPS $0.28 per share.

“Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results • Recorded total product revenue of $554 million in the quarter, an increase of 82% from the prior-year period, driven by increased sales of BRUKINSA® worldwide • Global sales of BRUKINSA totaled $308 million in the quarter, a”

BeOne Medicines Ltd. entered into Settlement and Termination Agreement with Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, Celgene Logistics Sàrl (effective 2023-08-01).

“On August 1, 2023, BeiGene, Ltd. ( "BeiGene") and its wholly-owned indirect subsidiary, BeiGene Switzerland GmbH, signed a Settlement and Termination Agreement (the “Agreement”) with Bristol-Myers Squibb Company (“BMS”), Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation, and Celgene Logistics Sàrl (collectively with BMS, “BMS-Celgene”), relating to the termination of the parties’ ongoing contractual relationships”

BeOne Medicines Ltd. terminated Option, Collaboration and License Agreement with Novartis Pharma AG valued at Mutual termination of the Option Agreement, effective immediately. (effective 2023-07-10).

“Item 1.02. Termination of a Material Definitive Agreement. As previously disclosed, on December 19, 2021, BeiGene Switzerland GmbH (“BeiGene Switzerland”), a wholly-owned indirect subsidiary of BeiGene, Ltd. (the “Company”), entered into an Option, Collaboration and License Agreement (the “Option Agreement”) with Novartis Pharma AG (“Novartis”), pursuant to which BeiGene Switzerland granted Novartis an exclusive time-based option to receive an exclusive license to develop, manufacture and commercialize the Company’s investigational TIGIT inhibitor ociperlimab in certain territories. On July 10, 2023, BeiGene Switzerland and Novartis entered into a Mutual Termination and Release Agreement (the “Termination Agreement”) to mutually terminate the Option Agreement, effective immediately.”

BeOne Medicines Ltd.: Shareholders approved Seventh Amended and Restated Memorandum and Articles of Association to comply with HK Listing Rules, with changes to inspection of register, annual meeting, meetings proceedings, votes, director terms, and auditor provisions (effective 2023-06-15).

“On June 15, 2023, at the 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) of BeiGene, Ltd. (the “Company”), the Company’s shareholders approved the Seventh Amended and Restated Memorandum and Articles of Association of the Company (the “Seventh Restated Articles”), which amended the Sixth Amended and Restated Memorandum and Articles of Association of the Company (the “Existing Articles”) to comply with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong (the “HK Listing Rules”).”

BeOne Medicines Ltd. shareholders approved Grant share repurchase mandate to Board of Directors (General Mandate to Repurchase Shares) at the 2023-06-15 meeting.

“(7) Ordinary resolution: within the parameters of the HK Listing Rules, to approve the granting of a share repurchase mandate to the Board of Directors to repurchase an amount of ordinary shares (excluding RMB shares) and/or ADSs, not exceeding 10% of the total number of issued ordinary shares (excluding RMB shares) of the Company as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, subject to the conditions described in the Proxy Statement (the “General Mandate to Repurchase Shares”): Votes For Votes Against Abstentions Broker Non- Votes 1,051,315,803 1,653,723 32,262 — Accordingly, the General Mandate to Repurchase Shares was approved.”

BeOne Medicines Ltd. shareholders approved Grant share issue mandate to Board of Directors (General Mandate to Issue Shares) at the 2023-06-15 meeting.

“(6) Ordinary resolution: within the parameters of the HK Listing Rules, to approve the granting of a share issue mandate to the Board of Directors to issue, allot or deal with (i) unissued ordinary shares (excluding our RMB Shares) and/or ADSs not exceeding 20% of the total number of issued ordinary shares (excluding RMB shares) of the Company and/or (ii) unissued RMB shares not exceeding 20% of the total number of issued RMB shares of the Company, each as of the date of passing of such ordinary resolution up to the next annual general meeting of shareholders of the Company, subject to the conditions described in the Proxy Statement (the “General Mandate to Issue Shares”): Votes For Votes Against Abstentions Broker Non- Votes 840,972,117 211,977,909 51,762 — Accordingly, the General Mandate to Issue Shares was approved.”

BeOne Medicines Ltd. shareholders approved Authorize Board of Directors to fix auditors' remuneration for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.

“(5) Ordinary resolution: to authorize the Board of Directors to fix the auditors’ remuneration for the fiscal year ending December 31, 2023: Votes For Votes Against Abstentions Broker Non- Votes 1,052,931,046 57,900 12,842 — Accordingly, the Board of Directors was authorized to fix the auditors’ remuneration for the fiscal year ending December 31, 2023.”

BeOne Medicines Ltd. shareholders approved Approve and ratify selection of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as reporting accounting firms for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.

“(4) Ordinary resolution: to approve and ratify the selection of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company’s reporting accounting firms for the fiscal year ending December 31, 2023: Votes For Votes Against Abstentions Broker Non- Votes 1,052,805,024 172,917 23,847 — Accordingly, the selection of Ernst & Young LLP, Ernst & Young and Ernst & Young Hua Ming LLP as the Company’s reporting accounting firms was approved and ratified.”

BeOne Medicines Ltd. shareholders approved Re-elect Dr. Alessandro Riva as Class I director at the 2023-06-15 meeting.

“(3) Ordinary resolution: to re-elect Dr. Alessandro Riva to serve as a Class I director until the 2026 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal: Votes For Votes Against Abstentions Broker Non- Votes 1,029,761,599 23,222,127 18,062 — Accordingly, Dr. Alessandro Riva was re-elected to serve as a Class I director.”

BeOne Medicines Ltd. shareholders approved Re-elect John V. Oyler as Class I director at the 2023-06-15 meeting.

“(2) Ordinary resolution: to re-elect John V. Oyler to serve as a Class I director until the 2026 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal: Votes For Votes Against Abstentions Broker Non- Votes 1,040,325,525 12,461,780 214,483 — Accordingly, John V. Oyler was re-elected to serve as a Class I director.”

BeOne Medicines Ltd. shareholders approved Re-elect Dr. Margaret Dugan as Class I director at the 2023-06-15 meeting.

“(1) Ordinary resolution: to re-elect Dr. Margaret Dugan to serve as a Class I director until the 2026 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal: Votes For Votes Against Abstentions Broker Non-Votes 1,043,071,109 9,915,997 14,682 — Accordingly, Dr. Margaret Dugan was re-elected to serve as a Class I director.”

BeOne Medicines Ltd. reported the three months ended March 31, 2023 results: revenue $447.8 million, net income $348.4 million, EPS $0.26 per share.

“faster than operational expenses, BeiGene is well positioned for future growth.” First Quarter 2023 Financial Results Revenue for the three months ended March 31, 2023, was $447.8 million, compared to $306.6 million in the same period of 2022. • Product revenue totaled $410.3 million for the three months ended March 31, 2023, compared to $261.6 million in the same”

BeOne Medicines Ltd. reported the year ended December 31, 2022 results: revenue 1,415,921.

“For the year ended December 31, 2022 For the year ended December 31, 2021 By Region Revenue COGS Gross Margin ratio Revenue COGS Gross Margin ratio China 840,032 276,729 67.1% 517,173 162,976 68.5% Ex-China 575,889 9,746 98.3% 659,110 1,930 99.7% Total 1,415,921 286,475 1,176,283 164,906”

BeOne Medicines Ltd. reported full year 2022 results: revenue $1.4 billion.

“Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively”

BeOne Medicines Ltd. reported fourth quarter 2022 results: revenue $380.1 million.

“Revenue for the fourth quarter and full year 2022 was $380.1 million and $1.4 billion, respectively”

BeOne Medicines Ltd. amended Amendment No. 3 to the Share Purchase Agreement with Amgen Inc. (effective 2023-01-30).

“On January 30, 2023, on account of the Company’s global growth, Amgen elected to relinquish its right to appoint a designated director to the Company’s board of directors, pursuant to an Amendment No. 3 to the Share Purchase Agreement (the “Amendment”).”

BeOne Medicines Ltd. reported the three months ended September 30, 2022 results: revenue $387.6 million, net income net loss of $557.6 million.

“into the U.S. dollar negatively impacted ending cash by $62.7 million in the three months ended September 30, 2022. Revenue for the three months ended September 30, 2022 was $387.6 million, compared to $206.4 million in the same period of 2021. • Product revenue totaled $349.5 million for the three months ended September 30, 2022, compared to $192.5 million in the”

Timothy Chen resigned as Director at BeOne Medicines Ltd..

“On June 22, 2022, Timothy Chen resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).”

Jane Huang resigned as Chief Medical Officer, Hematology at BeOne Medicines Ltd..

“On March 2, 2022, Jane Huang, M.D., Chief Medical Officer, Hematology of BeiGene, Ltd. (the “Company”), provided notice of her resignation from the Company effective April 3, 2022.”

Alessandro Riva was appointed as Director at BeOne Medicines Ltd..

“On February 1, 2022, the Board enlarged the Board from 11 to 12 members and appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. to fill the two vacancies.”

Margaret Dugan was appointed as Director at BeOne Medicines Ltd..

“On February 1, 2022, the Board enlarged the Board from 11 to 12 members and appointed Margaret Dugan, M.D. and Alessandro Riva, M.D. to fill the two vacancies.”